Billions on the table, GSK’s Hal Barron antes $120M cash to partner with a specialist in synthetic lethality
GSK R&D chief Hal Barron has turned to another Bay Area biotech for his latest oncology drug development pact, which could total billions for a preclinical deal that starts with $120 million in cash. And this one speaks directly to one of his favorite topics: synthetic lethality.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.